Author | Richard R. Kerr


FDA approves 2 PARP inhibitors for certain men with prostate cancer

May 21, 2020

The FDA has approved 2 poly (ADP-ribose) polymerase (PARP) inhibitors for men with metastatic castration-resistant prostate cancer who have certain genetic mutations, marking the first approvals of this newer drug class in prostate cancer.

Online prostate cancer videos earn poor grade for accuracy

May 18, 2020

Misinformation about prostate cancer is rampant online and significantly impacts patient care, study authors said at an American Urological Association press briefing. Researchers using machine learning have taken what they say is a first step to help vet the quality of online content.

Surveillance for small renal masses appears safe at 10 years

May 14, 2020

Data from a large registry showed that active surveillance for small renal masses was safe and noninferior to primary intervention at 10 years. In this video, senior author Phillip M. Pierorazio, MD, of Johns Hopkins University discusses results of the study presented as part of the AUA 2020 Virtual Experience.

Genetic testing’s role centers on advanced prostate cancer

April 07, 2020

In this interview, Leonard G. Gomella, MD, discusses the increasingly important role genetic testing plays in prostate cancer, current obstacles to testing, and when and how it will be carried out.